FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280522460> ?p ?o ?g. }

• W4280522460 endingPage "406" @default.
• W4280522460 startingPage "392" @default.
• W4280522460 abstract "Antibody-mediated rejection (AMR) is one of the major causes of graft loss after transplantation. Recently, the regulation of B cell differentiation and the prevention of donor-specific antibody (DSA) production have gained increased attention in transplant research. Herein, we established a secondary allogeneic in vivo skin transplant model to study the effects of romidepsin (FK228) on DSA. The survival of grafted skins was monitored daily. The serum levels of DSA and the number of relevant immunocytes in the recipient spleens were evaluated by flow cytometry. Then, we isolated and purified B cells from B6 mouse spleens in vitro by magnetic bead sorting. The B cells were cultured with interleukin-4 (IL-4) and anti-clusters of differentiation 40 (CD40) antibody with or without FK228 treatment. The immunoglobulin G1 (IgG1) and IgM levels in the supernatant were evaluated by enzyme-linked immunosorbent assay (ELISA). Quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and western blotting were conducted to determine the corresponding levels of messenger RNA (mRNA) and protein expression in cultured cells and the recipient spleens. The results showed that FK228 significantly improved the survival of allogeneic skin grafts. Moreover, FK228 inhibited DSA production in the serum along with the suppression of histone deacetylase 1 (HADC1) and HDAC2 and the upregulation of the acetylation of histones H2A and H3. It also inhibited the differentiation of B cells to plasma cells, decreased the transcription of positive regulatory domain-containing 1 (Prdm1) and X-box-binding protein 1 (Xbp1), and decreased the expression of phosphorylated inositol-requiring enzyme 1 α (p-IRE1α), XBP1, and B lymphocyte-induced maturation protein-1 (Blimp-1). In conclusion, FK228 could decrease the production of antibodies by B cells via inhibition of the IRE1α-XBP1 signaling pathway. Thus, FK228 is considered as a promising therapeutic agent for the clinical treatment of AMR." @default.
• W4280522460 created "2022-05-22" @default.
• W4280522460 creator A5013262234 @default.
• W4280522460 creator A5022248804 @default.
• W4280522460 creator A5030802139 @default.
• W4280522460 creator A5040407799 @default.
• W4280522460 creator A5046501238 @default.
• W4280522460 creator A5055597960 @default.
• W4280522460 creator A5077299462 @default.
• W4280522460 creator A5087164059 @default.
• W4280522460 date "2022-05-01" @default.
• W4280522460 modified "2023-10-16" @default.
• W4280522460 title "Romidepsin (FK228) improves the survival of allogeneic skin grafts through downregulating the production of donor-specific antibody via suppressing the IRE1α-XBP1 pathway" @default.
• W4280522460 cites W1648073061 @default.
• W4280522460 cites W1672219033 @default.
• W4280522460 cites W1970090817 @default.
• W4280522460 cites W1975213528 @default.
• W4280522460 cites W1980268334 @default.
• W4280522460 cites W1986045624 @default.
• W4280522460 cites W1988622164 @default.
• W4280522460 cites W1993624071 @default.
• W4280522460 cites W2005129842 @default.
• W4280522460 cites W2018016418 @default.
• W4280522460 cites W2018822911 @default.
• W4280522460 cites W2028943181 @default.
• W4280522460 cites W2045096857 @default.
• W4280522460 cites W2046517086 @default.
• W4280522460 cites W2058806464 @default.
• W4280522460 cites W2071959000 @default.
• W4280522460 cites W2081870862 @default.
• W4280522460 cites W2089198803 @default.
• W4280522460 cites W2093417809 @default.
• W4280522460 cites W2099013228 @default.
• W4280522460 cites W2112587694 @default.
• W4280522460 cites W2118944694 @default.
• W4280522460 cites W2126088939 @default.
• W4280522460 cites W2130241868 @default.
• W4280522460 cites W2130514605 @default.
• W4280522460 cites W2143952529 @default.
• W4280522460 cites W2154841949 @default.
• W4280522460 cites W2165608602 @default.
• W4280522460 cites W2192080449 @default.
• W4280522460 cites W2260507520 @default.
• W4280522460 cites W2266921405 @default.
• W4280522460 cites W2346655347 @default.
• W4280522460 cites W2461952548 @default.
• W4280522460 cites W2556153103 @default.
• W4280522460 cites W2577508976 @default.
• W4280522460 cites W2606086695 @default.
• W4280522460 cites W2792313850 @default.
• W4280522460 cites W2887502771 @default.
• W4280522460 cites W2890471025 @default.
• W4280522460 cites W2892130773 @default.
• W4280522460 cites W2896677671 @default.
• W4280522460 cites W2912267252 @default.
• W4280522460 cites W2915262193 @default.
• W4280522460 cites W2916445693 @default.
• W4280522460 cites W2962970073 @default.
• W4280522460 cites W2963736364 @default.
• W4280522460 cites W2989908439 @default.
• W4280522460 cites W3004920144 @default.
• W4280522460 cites W3005155026 @default.
• W4280522460 cites W3009549504 @default.
• W4280522460 cites W3018430775 @default.
• W4280522460 cites W3021406932 @default.
• W4280522460 cites W3046130419 @default.
• W4280522460 cites W3048717461 @default.
• W4280522460 cites W3084307842 @default.
• W4280522460 cites W3085446910 @default.
• W4280522460 cites W3127695018 @default.
• W4280522460 cites W3155345388 @default.
• W4280522460 cites W3160863466 @default.
• W4280522460 cites W3162317822 @default.
• W4280522460 cites W3169589874 @default.
• W4280522460 cites W3181190995 @default.
• W4280522460 cites W3199553890 @default.
• W4280522460 doi "https://doi.org/10.1631/jzus.b2100780" @default.
• W4280522460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35557040" @default.
• W4280522460 hasPublicationYear "2022" @default.
• W4280522460 type Work @default.
• W4280522460 citedByCount "0" @default.
• W4280522460 crossrefType "journal-article" @default.
• W4280522460 hasAuthorship W4280522460A5013262234 @default.
• W4280522460 hasAuthorship W4280522460A5022248804 @default.
• W4280522460 hasAuthorship W4280522460A5030802139 @default.
• W4280522460 hasAuthorship W4280522460A5040407799 @default.
• W4280522460 hasAuthorship W4280522460A5046501238 @default.
• W4280522460 hasAuthorship W4280522460A5055597960 @default.
• W4280522460 hasAuthorship W4280522460A5077299462 @default.
• W4280522460 hasAuthorship W4280522460A5087164059 @default.
• W4280522460 hasBestOaLocation W42805224602 @default.
• W4280522460 hasConcept C104317684 @default.
• W4280522460 hasConcept C126322002 @default.
• W4280522460 hasConcept C127561419 @default.
• W4280522460 hasConcept C150903083 @default.
• W4280522460 hasConcept C153911025 @default.
• W4280522460 hasConcept C159654299 @default.
• W4280522460 hasConcept C203014093 @default.

• next